SA 58
Alternative Names: SA58; SA58 nasal sprayLatest Information Update: 28 Jan 2026
At a glance
- Originator Sinovac Biotech
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In the elderly, Prevention, In volunteers, In adults) in China (Intranasal)
- 30 Dec 2022 Clinical trials in COVID-2019 infections in China (Intranasal) (NCT05664919)
- 27 Dec 2022 Sinovac Life Sciences initiates a clinical trial for COVID-2019 in China (Intranasal) (NCT05667714)